0.10Open0.10Pre Close0 Volume67 Open Interest22.50Strike Price0.00Turnover456.29%IV-3.32%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry0.10Time Value100Contract SizeAmericanOptions Type-0.2060Delta0.3361Gamma231.70Leverage Ratio-5.1908Theta0.0000Rho-47.72Eff Leverage0.0005Vega
Cullinan Therapeutics Stock Discussion
NEWS
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
• $Cullinan Therapeutics(CGEM.US)$ +22.4% (Cullinan Management and Taiho Pharmaceutical to collaborate to jointly develop and commercialize CLN081/TAS6417 and Taiho's acquisition of Cullinan Pearl)
• $Lordstown Motors(RIDE.US)$ +17.2% (closes asset purchase agreement with Foxconn)
• $Applovin(APP.US)$ +15.5%(In reaction to earnings)
• $SmartRent(SMRT.US)$ +15.4%(In reaction to earnings)
• $Coupang(CPNG.US)$ +14.3%(In reaction to earn...
No comment yet